CUV has also more than halved over the last 6-months as the high Beta biotech growth names have been throw into the naughty corner – the stories been the same in the US. This dermatology focused business is not uncommon to volatility hence at this stage we would be considering an aggressive play closer to $15 but rising competition for CUV’s Scenesse therapy would keep us cautious from a commitment perspective.
MM is neutral CUV
Add To Hit List
